The Effect of Therapeutic Drug Monitoring on Safety and Efficacy of Voriconazole in Invasive Fungal Infections: A Randomized Controlled Trial-Reference-Cited by-同舟云学术

The Effect of Therapeutic Drug Monitoring on Safety and Efficacy of Voriconazole in Invasive Fungal Infections: A Randomized Controlled Trial

Published:2012-07-03 Issue:8 Volume:55 Page:1080-1087
ISSN:1537-6591
Container-title:Clinical Infectious Diseases
language:en
Short-container-title:

Author:

Park Wan Beom,Kim Nak-Hyun,Kim Kye-Hyung,Lee Seung Hwan,Nam Won-Seok,Yoon Seo Hyun,Song Kyoung-Ho,Choe Pyoeng Gyun,Kim Nam Joong,Jang In-Jin,Oh Myoung-don,Yu Kyung-Sang

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Microbiology (medical)

Link

http://academic.oup.com/cid/article-pdf/55/8/1080/17350546/cis599.pdf

Reference24 articles.

1. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America;Walsh;Clin Infect Dis,2008

2. Adverse reactions to voriconazole;Boyd;Clin Infect Dis,2004

3. Hallucinations during voriconazole therapy;Zonios;Clin Infect Dis,2008

4. Hepatotoxicity of oral and intravenous voriconazole in relation to cytochrome P450 polymorphisms;Levin;J Antimicrob Chemother,2007

5. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes;Pascual;Clin Infect Dis,2008

Cited by 332 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Voriconazole therapeutic drug monitoring including analysis of CYP2C19 phenotype in immunocompromised pediatric patients with invasive fungal infections;European Journal of Clinical Pharmacology;2024-09-06

2. Voriconazole as an alternative oral treatment in fluconazole-resistant urinary candidiasis;Infectious Diseases Now;2024-09

3. Associated factors with voriconazole plasma concentration: a systematic review and meta-analysis;Frontiers in Pharmacology;2024-08-23

4. Influence of C-reactive protein on the pharmacokinetics of voriconazole in relation to the CYP2C19 genotype: a population pharmacokinetics analysis;Frontiers in Pharmacology;2024-08-20

5. Questioning the Design of Non‐Inferiority Trials: The Strange Case for Therapeutic Drug Monitoring Absence in Phase III Trials;Clinical Pharmacology & Therapeutics;2024-08-09